The purpose of this study is to investigate the efficacy of retapamulin to reduce carriage of
MRSA via a randomized, double-blind, placebo-controlled clinical study testing retapamulin
among patients with confirmed mupirocin-resistant nasal and/or rectal MRSA colonization. The
sample size will include 27 subjects in each of the two arms of the study (retapamulin versus
placebo) for a total of 54 subjects. Participants who are found to be nasal and/or rectal
colonized with MRSA will be randomized to receive either retapamulin or placebo applied
nasally and rectally for a total of 5 days. Nasal and rectal swabs will be collected at
pre-defined time points during study duration (screening swab, swab one week after completion
of topical therapy, swab 4 weeks after completion of topical therapy) to assess MRSA
colonization status. The colonization rates of both groups will be assessed via Fisher's
Exact Test.
Phase:
Phase 3
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health